Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
复制标题
DOI：
10.1093/jac/dkx049
复制
发表时间：
2017-06-01
影响因子：
5.2
通讯作者：
Legakis, Nicholas J.
中科院分区：
文献类型：
--
作者：
Falagas, Matthew E.;Skalidis, Tilemachos;Legakis, Nicholas J.
背景：头孢地罗 (S-649266) 是一种铁载体头孢菌素，利用一种进入革兰氏阴性菌周质空间的新机制，对 ESBL 和碳青霉烯酶广泛稳定。方法：测试了从 18 家希腊医院临床标本中分离的碳青霉烯类耐药革兰氏阴性菌对头孢地罗、美罗培南、头孢他啶、头孢吡肟、头孢他啶/阿维巴坦、头孢洛嗪/他唑巴坦、氨曲南、阿米卡星、环丙沙星、粘菌素和替加环素。采用肉汤微量稀释板测定 MIC。结果：总共研究了 189 种非发酵革兰氏阴性菌（107 种鲍曼不动杆菌和 82 种铜绿假单胞菌）和 282 种肠杆菌科细菌（包括 244 种肺炎克雷伯菌、14 种阴沟肠杆菌和 11 种斯氏普罗维登斯菌）。对于鲍曼不动杆菌和铜绿假单胞菌，头孢地考的 MIC90 均为 0.5 mg/L。对于肺炎克雷伯菌、阴沟肠球菌和斯氏假单胞菌，头孢菌素的 MIC90 分别为 1、1 和 0.5 mg/L。替加环素是第二大活性抗生素，其次是粘菌素。结论：头孢地考在体外对碳青霉烯类耐药革兰氏阴性菌表现出比对照抗生素更强的抗菌活性。
Background: Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases.Methods: A collection of carbapenem-resistant Gram-negative bacteria isolated from clinical specimens in 18 Greek hospitals was tested for susceptibility to cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline. Broth microdilution plates were used to determine MICs.Results: In total 189 non-fermentative Gram-negative bacteria (107 Acinetobacter baumannii and 82 Pseudomonas aeruginosa) and 282 Enterobacteriaceae (including 244 Klebsiella pneumoniae, 14 Enterobacter cloacae and 11 Providencia stuartii) were studied. For both A. baumannii and P. aeruginosa the MIC90 of cefiderocol was 0.5 mg/L. For K. pneumoniae, E. cloacae and P. stuartii the MIC90 of cefiderocol was 1, 1 and 0.5 mg/L, respectively. Tigecycline was the second most active antibiotic, followed by colistin.Conclusions: Cefiderocol exhibited greater antimicrobial activity in vitro against carbapenem-resistant Gram-negative bacteria than comparator antibiotics.